Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis
Chemotherapiewechsel bei lokalisiertem Pankreaskarzinom: systematische Übersicht und Metaanalyse
British Journal of Surgery · 01.10.2024 · 111 (10)
DOI: 10.1093/bjs/znae244 ↗Auf einen Blick
Bei lokalisiertem Pankreasgangadenokarzinom wurde ein Chemotherapiewechsel nach unzureichendem Ansprechen oder Toxizität untersucht. Die gepoolte Resektionsrate nach Wechsel betrug 42,0 %.
Fragestellung
Welche Daten gibt es zum Einsatz und Effekt eines Chemotherapiewechsels bei lokalisiertem Pankreasgangadenokarzinom?
Methode
Systematische Suche in Embase, MEDLINE (Ovid), Web of Science, Cochrane und Google Scholar bis 1. Dezember 2023; gepoolte Analyse mit Random-effects-Modell.
Ergebnisse
5 retrospektive Studien mit 863 Patient:innen. 226/863 erhielten einen Chemotherapiewechsel. Wechselrate 20,5 % (95 %-KI 10,5–36,3 %); Resektionsrate 42,0 % (95 %-KI 16,6–72,5 %); RR 0,88 (95 %-KI 0,65–1,18).
Schlussfolgerung der Autor:innen
Eine von fünf Personen mit lokalisiertem Pankreasgangadenokarzinom erhielt nach unzureichendem Ansprechen oder Toxizität einen Chemotherapiewechsel. Die gepoolte Resektionsrate betrug 42 %, das Gesamtüberleben war ähnlich.
Kernaussagen
- Chemotherapiewechsel bei 226 von 863 Patient:innen
- Wechselrate 20,5 % und Resektionsrate 42,0 %
- Kein klarer Vorteil gegenüber alleiniger Erstlinientherapie
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift British Journal of Surgery, online erschienen am 14.10.2024. Verfasst von Esther N Dekker und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, ZonMw, The Dutch Cancer Society.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the available data on the use and effect of chemotherapy switch, as reported in the literature.
Methods
A systematic search was conducted in Embase, MEDLINE (Ovid), the Web of Science, Cochrane, and Google Scholar on 1 December 2023. The main outcomes were the proportion of patients who underwent chemotherapy switch and the carbohydrate antigen 19-9 response and resection, R0 resection, and ypN0 resection rates after chemotherapy switch. Data were pooled using a random-effects model.
Results
A total of five retrospective studies, representing 863 patients with localized pancreatic ductal adenocarcinoma, were included and 226 of the 863 patients underwent chemotherapy switch. In four studies, first-line chemotherapy consisted of 5-fluorouracil/leucovorin/irinotecan with oxaliplatin (‘FOLFIRINOX’) and patients were switched to gemcitabine with nab-paclitaxel. Reasons for chemotherapy switch included an inadequate biochemical, clinical, or radiological response, or toxicity. Three studies compared patients who underwent chemotherapy switch with patients who only received first-line chemotherapy and found that the proportion of patients who underwent chemotherapy switch was 20.5% (95% c.i. 10.5% to 36.3%). The pooled resection rate after chemotherapy switch was 42.0% (95% c.i. 16.6% to 72.5%). Two studies compared the chance of resection after chemotherapy switch versus first-line chemotherapy alone and found a risk ratio of 0.88 (95% c.i. 0.65 to 1.18). Two studies, with a combined total of 576 patients, found similar postoperative survival for patients who underwent chemotherapy switch and patients who only received first-line chemotherapy.
Conclusion
One in five patients with localized pancreatic ductal adenocarcinoma underwent chemotherapy switch after an inadequate response or toxicity to first-line chemotherapy. The pooled resection rate after chemotherapy switch was 42% and similar in overall survival compared with first-line chemotherapy only. Three ongoing trials are investigating chemotherapy switch in patients with an inadequate radiological or carbohydrate antigen 19-9 response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
- Department of Surgery, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, The Netherlands.
- Department of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Surgery, Amsterdam UMC, Location University of Amsterdam, Amsterdam, The Netherlands.
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
ORCID-Profile: Esther N Dekker, Marc G H Besselink, Bianca Mostert, Motaz Qadan, Bas Groot Koerkamp
Förderung
- NCI NIH HHS
- ZonMw
- The Dutch Cancer Society
Zitieren
APA
Dekker, E. N., Narayan, R. R., Ahmami, M. A., Meddouch, A., Verkolf, E. M. M., Gehrels, A. M., Besselink, M. G. H., van Eijck, C. H. J., Homs, M. Y. V., Mostert, B., O'Kane, G. M., de Wilde, R. F., Wilmink, J. W., O'Reilly, E. M., Qadan, M., & Groot Koerkamp, B. (2024). Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. British Journal of Surgery, 111(10). https://doi.org/10.1093/bjs/znae244
Vancouver
Dekker EN, Narayan RR, Ahmami MA, Meddouch A, Verkolf EMM, Gehrels AM, et al. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. British Journal of Surgery. 2024;111(10). doi:10.1093/bjs/znae244
BibTeX
@article{Dekker2024,
author = {Dekker, Esther N and Narayan, Raja R and Ahmami, Mohamed A and Meddouch, Anis and Verkolf, Eva M M and Gehrels, Anne M and Besselink, Marc G H and van Eijck, Casper H J and Homs, Marjolein Y V and Mostert, Bianca and O'Kane, Grainne M and de Wilde, Roeland F and Wilmink, Johanna W and O'Reilly, Eileen M and Qadan, Motaz and Groot Koerkamp, Bas},
title = {Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis},
journal = {British Journal of Surgery},
year = {2024},
volume = {111},
number = {10},
doi = {10.1093/bjs/znae244}
}
EUVIMED